S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
How to profit from the new boom in gold (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Obama’s 2024 Confession (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
How to profit from the new boom in gold (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:REPL

Replimune Group (REPL) Stock Price, News & Analysis

$8.71
-0.15 (-1.69%)
(As of 02/28/2024 ET)
Today's Range
$8.71
$9.09
50-Day Range
$6.87
$9.31
52-Week Range
$5.89
$24.81
Volume
1.05 million shs
Average Volume
1.63 million shs
Market Capitalization
$534.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.25

Replimune Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
350.6% Upside
$39.25 Price Target
Short Interest
Healthy
13.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.32) to ($3.06) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

Medical Sector

80th out of 958 stocks

Biological Products, Except Diagnostic Industry

10th out of 151 stocks


REPL stock logo

About Replimune Group Stock (NASDAQ:REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Stock Price History

REPL Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Replimune Group Inc (REPL)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
REPL Feb 2024 30.000 put
What's Going On With Cancer-Focused Replimune Stock Today?
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
2/29/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/16/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:REPL
Fax
N/A
Employees
284
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$39.25
High Stock Price Target
$52.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+350.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-174,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.87 per share

Miscellaneous

Free Float
48,742,000
Market Cap
$534.71 million
Optionable
Optionable
Beta
1.22
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Philip Astley-Sparke F.S.A. (Age 53)
    CEO & Director
    Comp: $1.07M
  • Dr. Sushil Patel Ph.D. (Age 53)
    Chief Strategy Officer
    Comp: $665.05k
  • Dr. Robert Coffin Ph.D. (Age 59)
    Founder, President, Chief Research & Development Officer and Director
    Comp: $785.89k
  • Ms. Emily Luisa Hill (Age 44)
    Chief Financial Officer
  • Dr. Colin A. Love Ph.D. (Age 66)
    Chief Operating Officer
    Comp: $419.37k
  • Mr. Andrew Schwendenman (Age 48)
    Chief Accounting Officer & Treasurer
  • Dr. Pamela Esposito Ph.D. (Age 50)
    Chief Business Officer
    Comp: $464.63k
  • Ms. Tanya N. Lewis M.S. (Age 53)
    Chief Development Operations Officer
    Comp: $4.7k
  • Mr. Christopher Sarchi (Age 56)
    Chief Commercial Officer
  • Dr. Konstantinos Xynos M.B.A. (Age 58)
    M.D., Ph.D., Chief Medical Officer














REPL Stock Analysis - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Replimune Group's shares. Their REPL share price targets range from $13.00 to $52.00. On average, they predict the company's share price to reach $39.25 in the next twelve months. This suggests a possible upside of 350.6% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2024?

Replimune Group's stock was trading at $8.43 at the beginning of the year. Since then, REPL stock has increased by 3.3% and is now trading at $8.71.
View the best growth stocks for 2024 here
.

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024.
View our REPL earnings forecast
.

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) posted its quarterly earnings results on Thursday, February, 8th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.12.

What ETFs hold Replimune Group's stock?

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO),

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.53%), Price T Rowe Associates Inc. MD (9.53%), Vanguard Group Inc. (4.46%), Goldman Sachs Group Inc. (3.65%), Dimensional Fund Advisors LP (2.24%) and Northern Trust Corp (0.78%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis.
View institutional ownership trends
.

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:REPL) was last updated on 2/29/2024 by MarketBeat.com Staff